Sign in Subscribe
Chairpersons

John Houston to Retire as Arvinas CEO, President and Chairperson to Remain Involved

Strategic Insights

— 1 min read

Dr. Houston, a seasoned executive with over 35 years of experience in the pharmaceutical and biotech industries, has informed the Arvinas Board of Directors of his plans to retire as CEO and President. He will remain Chairperson of the Board and oversee the search for his successor. During his tenure, Dr. Houston has led the company's success in moving six programs into the clinic, reporting the first positive pivotal Phase 3 trial, and demonstrating the efficacy of orally administered PROTACs.

Key Takeaways:

  • Dr. John Houston, Ph.D., will retire as President and CEO of Arvinas, having served in the role since September 2017.
  • Dr. Houston will remain Chairperson of the Arvinas Board of Directors, a position he was appointed to in 2023.
  • The Arvinas Board of Directors has begun searching for a new CEO to succeed Dr. Houston.
  • Dr. Houston has over 35 years of experience in the pharmaceutical and biotech industries.
  • During his tenure, Arvinas has achieved several milestones, including moving six programs into the clinic and reporting the first positive pivotal Phase 3 trial.
  • Dr. Houston played a key role in Arvinas' success, leveraging his experience to guide the company's growth and development.
  • The company is currently progressing multiple investigational drugs through clinical development programs.
  • These include vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer, and others.
  • Arvinas is well-positioned to benefit many patients in the years to come, thanks to Dr. Houston's efforts.

Statistics:

  • 35 years: Dr. Houston's experience in the pharmaceutical and biotech industries.
  • 6: Number of programs Arvinas has moved into the clinic under Dr. Houston's leadership.
  • 2017, January: Dr. Houston joined Arvinas as President of Research and Development and Chief Scientific Officer.
  • 2017, September: Dr. Houston was appointed President and CEO of Arvinas.
  • 2023: Dr. Houston was appointed Chairperson of the Arvinas Board of Directors.

Sources:

  • Arvinas, Inc. (2025, July 9). John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor. Globe Newswire.
  • Arvinas, Inc. (2024, December 31). Arvinas Announces Year-End Results and Provides Business Update. Globe Newswire.

Read more